1. Effectiveness evaluation of hyaluronic acid-based commercial eye drops to treat ophthalmic dry eye disease
- Author
-
Jon Andrade del Olmo, Virginia Sáez Martínez, Nagore Martínez de Cestafe, José María Alonso, Cristina Olavarrieta, Miguel Ucelay López de Heredia, Sandra Benito Cid, and Raúl Pérez González
- Subjects
Dry eye disease ,Hyaluronic acid molecular weight ,Gamma-polyglutamic acid ,Ex vivo ocular mucoadhesion properties ,DayDrop Advanced® eye drops ,Ophthalmic applications ,Biochemistry ,QD415-436 - Abstract
Nowadays, hyaluronic acid (HA) eye drops are widely used to combat ophthalmic dry eye disease (DED). Till the date, almost all commercialized HA eye drops are single-ingredient despite not displaying significantly different clinical effects (Artelac Splash®). Consequently, scientists are making great efforts to combine HA with other compounds to overcome more successfully DED (trometamol in Hyabak®, sorbitol in HyloComod®). Gamma-polyglutamic acid (γ-PGA) is another novel polymer that could induce a powerful synergistic effect on HA for DED treatment. To the best of our knowledge, eye drops combining HA and γ-PGA neither have been marketed nor scientific studies have been published so far. Fortunately, DayDrop Advanced® eye drop has been recently commercialized with HA + γ-PGA technology. In this work, DayDrop Advanced®, Hyabak®, HyloComod® and Artelac Splash® were compared evaluating their efficacy to treat DED and residence time in eye due to their distinct physicochemical and rheological properties. As key research point, DayDrop Advanced® demonstrated an improved immediate hydration, protection against corneal dehydration, anti-inflammatory, anti-hyaluronidase and ocular mucoadhesion activities than the rest of artificial tears. These phenomena highlight new generation DayDrop Advanced® combining HA + γ-PGA technology as the leading eye drops to treat more durably and effectively DED.
- Published
- 2024
- Full Text
- View/download PDF